Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
The primary objective of this study is to evaluate the efficacy of blinatumomab.
B Precursor Acute Lymphoblastic Leukemia|Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DRUG: Blinatumomab
Number of Participants with Complete Remission (CR), Up to 84 days|Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh), Up to 84 days
Number of Participants with Treatment-emergent Adverse Events (TEAEs), Up to approximately 240 days|Number of Participants with Serious TEAEs, Up to approximately 2 years|Number of Participants with Treatment-related TEAEs, Up to approximately 240 days|Number of Participants with Adverse Events of Interest, Up to approximately 240 days|Steady State Concentration (Css) of Blinatumomab, Days 3, 8, 9 and 29|Clearance of Blinatumomab, Days 3, 8, 9 and 29|Overall Survival (OS) Rate, Up to approximately 2 years|Relapse-Free Survival (RFS) Rate, Up to approximately 2 years|Number of Participants who Receive Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT), Up to approximately 2 years|100-day Mortality Rate After alloHSCT, Up to approximately 2 years|Number of Participants with Anti-blinatumomab Antibody (ADA) Formation, Up to approximately 240 days|Minimal Residual Disease (MRD) Response, Up to 84 days
The primary objective of this study is to evaluate the efficacy of blinatumomab.